Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Long-acting immune fusion protein for treating diabetes mellitus

A technology of fusion protein and diabetes, which is applied in the field of biomedicine to achieve the effect of easy affinity and prolonging the half-life of drugs

Active Publication Date: 2013-07-17
JIANGSU JIANDE BIOLOGICAL PHARMA
View PDF5 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, because Exenatide abroad is fully chemically synthesized, there are many steps in the chemical synthesis method, and the cost is relatively expensive. The domestic price of 5 μg of finished product is about 300 yuan, which is 5 times that of insulin.
The preparation of Exendin-4 by genetic engineering will greatly reduce the production cost. Many domestic units try to express it with prokaryotic expression system to reduce the cost. However, because Exendin-4 is only a 39 amino acid polypeptide, the expression level in Escherichia coli is relatively low. Low, downstream purification is difficult, and the yield is low, so it is difficult to succeed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Long-acting immune fusion protein for treating diabetes mellitus
  • Long-acting immune fusion protein for treating diabetes mellitus
  • Long-acting immune fusion protein for treating diabetes mellitus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] one, Exendin-4-IgG4 Cloning of Immunofusion Protein Gene

[0032] 1. Gene Synthesis

[0033] Entrusted Shanghai Jierui Bioengineering Co., Ltd. to pass the linker peptide (G4S) to the gene encoding Exendin-4 3 , linked to the IgG4 gene encoding the heavy chain constant region of the human antibody, and synthesized to encode Exendin-4-Igγ 4 The gene sequence, the nucleotide sequence of which is shown in SEQ No.1, is digested with Hind III and EcoRI restriction enzymes, and then connected to the pBL expression vector to obtain Exendin-4-Igγ 4 / pBL vector, where AAGCTT and GAATTC are restriction sites for Hind III and EcoRI, respectively.

[0034] Exendin-4-Igγ 4 The amino acid sequence of the encoded protein is shown in SEQ No.2, which includes the signal peptide sequence, Exendin-4 and IgG4 constant regions, wherein METDTLLLWVLLLWVPGSTG is the signal peptide sequence.

[0035] Similarly, Shanghai Jierui Bioengineering Co., Ltd. was entrusted to link the coding ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention provides a long-acting immune fusion protein for treating diabetes mellitus. The immune protein is an Exendin-4-IgG4 immune fusion protein. The long-acting immune fusion protein has the advantages that the Exendin-4-IgG4 immune fusion protein has functions of promoting insulin secretion, suppressing programmed apoptosis of beta-cells, stimulating multiplication of the beta-cells, reducing the glucagon level, retarding gastric emptying, reducing ingestion appetite and the like, in-vivo blood glucose is reduced in multiple ways without causing hypoglycemia, the effective phase of the Exendin-4-IgG4 immune fusion protein is longer than that of Exendin-4 immune fusion protein, a certain weight loss effect can be realized after Exendin-4-IgG4 immune fusion proteins are used for a long time, and the long-acting immune fusion protein can be used for treating type-II diabetes mellitus.

Description

technical field [0001] The invention provides a long-acting immune fusion protein for treating diabetes and belongs to the technical field of biomedicine. Background technique [0002] With the changes in people's diet structure and lifestyle, the incidence of diabetes, a metabolic disorder characterized by chronic hyperglycemia, is rising rapidly. On May 16, 2012, the "2012 World Health Statistics" report released in Geneva indicated that one in ten adults in the world suffers from diabetes (http: / / www.cmt.com.cn / ). According to statistics, at the end of the 1970s, the prevalence of diabetes in China was less than 1%. By April 2012, the prevalence of diabetes in residents aged 18 and over in my country was 9.7%. The rate is as high as 19.6%. There are about 97 million adult diabetic patients in the country, and the development of the affected population is tending to be younger. Active prevention and treatment of diabetes has become one of the important tasks in the fiel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K19/00C12N15/62C12N15/63C12N5/10A61K38/26A61K47/48A61P3/10
CPCA61K38/1703A61K38/1774A61K38/22A61P3/10C07K14/57563C07K2319/30
Inventor 胡品良杨思怡马金伟李闯陈宏周峰陈雁冰周茜侯乔峰万露赵彩丽
Owner JIANGSU JIANDE BIOLOGICAL PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com